KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Marta Román(Clinica Universidad de Navarra), Ignacio Gil‐Bazo(Navarre Institute of Health Research), Ernest Nadal(Institut d'Investigació Biomédica de Bellvitge), Iosune Baraibar(Breast Cancer Research Foundation), Inés López(Universidad de Navarra), Silvestre Vicent(Chartered Institute of Management Accountants), Christian Rolfo(Icahn School of Medicine at Mount Sinai)
Cited by 306
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642